BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 33022137)

  • 21. Mogamulizumab Treatment Elicits Autoantibodies Attacking the Skin in Patients with Adult T-Cell Leukemia-Lymphoma.
    Suzuki Y; Saito M; Ishii T; Urakawa I; Matsumoto A; Masaki A; Ito A; Kusumoto S; Suzuki S; Hiura M; Takahashi T; Morita A; Inagaki H; Iida S; Ishida T
    Clin Cancer Res; 2019 Jul; 25(14):4388-4399. PubMed ID: 31018922
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mogamulizumab: An Anti-CC Chemokine Receptor 4 Antibody for T-Cell Lymphomas.
    Moore DC; Elmes JB; Shibu PA; Larck C; Park SI
    Ann Pharmacother; 2020 Apr; 54(4):371-379. PubMed ID: 31648540
    [No Abstract]   [Full Text] [Related]  

  • 23. Molecular analysis of loss of CCR4 expression during mogamulizumab monotherapy in an adult T cell leukemia/lymphoma patient.
    Taguchi M; Imaizumi Y; Sasaki D; Higuchi T; Tsuruda K; Hasegawa H; Taguchi J; Sawayama Y; Imanishi D; Hata T; Yanagihara K; Yoshie O; Miyazaki Y
    Ann Hematol; 2015 Apr; 94(4):693-5. PubMed ID: 25338968
    [No Abstract]   [Full Text] [Related]  

  • 24. cDNA-Based Mutation Screening Using a Combination of High-Resolution Melting Curve and Fragment Analysis Facilitates Efficient CCR4 Mutation Analysis in Adult T-Cell Leukemia/Lymphoma.
    Mizuta S; Yamane N; Mononobe S; Komai T; Koba Y; Kawata T; Ukyo N; Tamekane A; Watanabe M
    Am J Clin Pathol; 2020 Jul; 154(2):236-241. PubMed ID: 32367127
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and effectiveness of mogamulizumab in relapsed or refractory adult T-cell leukemia-lymphoma.
    Ishitsuka K; Yurimoto S; Tsuji Y; Iwabuchi M; Takahashi T; Tobinai K
    Eur J Haematol; 2019 May; 102(5):407-415. PubMed ID: 30740787
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical Application of Anti-CCR4 Monoclonal Antibody.
    Ueda R
    Oncology; 2015; 89 Suppl 1():16-21. PubMed ID: 26550987
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CCR4 frameshift mutation identifies a distinct group of adult T cell leukaemia/lymphoma with poor prognosis.
    Yoshida N; Miyoshi H; Kato T; Sakata-Yanagimoto M; Niino D; Taniguchi H; Moriuchi Y; Miyahara M; Kurita D; Sasaki Y; Shimono J; Kawamoto K; Utsunomiya A; Imaizumi Y; Seto M; Ohshima K
    J Pathol; 2016 Apr; 238(5):621-6. PubMed ID: 26847489
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent advances in the treatment of adult T-cell leukemia-lymphomas.
    Utsunomiya A; Choi I; Chihara D; Seto M
    Cancer Sci; 2015 Apr; 106(4):344-51. PubMed ID: 25613789
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical impact of the CONUT score and mogamulizumab in adult T cell leukemia/lymphoma.
    Ureshino H; Kusaba K; Kidoguchi K; Sano H; Nishioka A; Itamura H; Yoshimura M; Yokoo M; Shindo T; Kubota Y; Ando T; Kojima K; Sueoka E; Kimura S
    Ann Hematol; 2019 Feb; 98(2):465-471. PubMed ID: 30264165
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mogamulizumab for relapsed adult T-cell leukemia-lymphoma: Updated follow-up analysis of phase I and II studies.
    Ishida T; Utsunomiya A; Jo T; Yamamoto K; Kato K; Yoshida S; Takemoto S; Suzushima H; Kobayashi Y; Imaizumi Y; Yoshimura K; Kawamura K; Takahashi T; Tobinai K; Ueda R
    Cancer Sci; 2017 Oct; 108(10):2022-2029. PubMed ID: 28776876
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Resistance to mogamulizumab is associated with loss of CCR4 in cutaneous T-cell lymphoma.
    Beygi S; Duran GE; Fernandez-Pol S; Rook AH; Kim YH; Khodadoust MS
    Blood; 2022 Jun; 139(26):3732-3736. PubMed ID: 35436328
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mogamulizumab for the treatment of adult T-cell leukemia/lymphoma.
    de Lartigue J
    Drugs Today (Barc); 2012 Oct; 48(10):655-60. PubMed ID: 23110261
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Companion diagnostics "POTELIGEO TEST IHC/FCM" used with "POTELIGEO" (mogamulizumab) for adult T-cell leukemia-lymphoma (ATL) treatment].
    Goami T
    Rinsho Byori; 2014 May; 62(5):450-6. PubMed ID: 25051659
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and efficacy profile of mogamulizumab (Poteligeo) in the treatment of cancers: an update evidence from 14 studies.
    Zhang T; Sun J; Li J; Zhao Y; Zhang T; Yang R; Ma X
    BMC Cancer; 2021 May; 21(1):618. PubMed ID: 34039310
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Adult T-cell leukemia-lymphoma complicated by Takotsubo cardiomyopathy and HTLV-1-associated myelopathy after treatment with the anti-CCR4 antibody mogamulizumab].
    Yamanaka S; Nakayama K; Tamai H; Sakamaki M; Inokuchi K
    Rinsho Ketsueki; 2017; 58(4):309-314. PubMed ID: 28484158
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-CCR4 monoclonal antibody mogamulizumab for the treatment of EBV-associated T- and NK-cell lymphoproliferative diseases.
    Kanazawa T; Hiramatsu Y; Iwata S; Siddiquey M; Sato Y; Suzuki M; Ito Y; Goshima F; Murata T; Kimura H
    Clin Cancer Res; 2014 Oct; 20(19):5075-84. PubMed ID: 25117294
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Population Pharmacokinetic Modeling of Mogamulizumab in Adults With Cutaneous T-Cell Lymphoma or Adult T-Cell Lymphoma.
    Mukai M; Maeda H; Narushima K; Mould DR; Greene D
    J Clin Pharmacol; 2020 Jan; 60(1):58-66. PubMed ID: 31840838
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Mogamulizumab for the treatment of ATL and PTCL].
    Tsukasaki K
    Gan To Kagaku Ryoho; 2015 May; 42(5):553-7. PubMed ID: 26054089
    [No Abstract]   [Full Text] [Related]  

  • 39. Safety and efficacy of mogamulizumab in patients with adult T-cell leukemia-lymphoma in Japan: interim results of postmarketing all-case surveillance.
    Ishitsuka K; Yurimoto S; Kawamura K; Tsuji Y; Iwabuchi M; Takahashi T; Tobinai K
    Int J Hematol; 2017 Oct; 106(4):522-532. PubMed ID: 28597329
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Successful treatment of a patient with adult T cell leukemia/lymphoma using anti-CC chemokine receptor 4 monoclonal antibody mogamulizumab followed by allogeneic hematopoietic stem cell transplantation.
    Motohashi K; Suzuki T; Kishimoto K; Numata A; Nakajima Y; Tachibana T; Ohshima R; Kuwabara H; Tanaka M; Tomita N; Ishigatsubo Y; Fujisawa S
    Int J Hematol; 2013 Aug; 98(2):258-60. PubMed ID: 23801427
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.